DrugDashboards

Glycopyrrolate

Glycopyrrolate · GLYCOPYRROLATE .2 mg/mL · Injection · Intramuscular; Intravenous · Somerset Therapeutics, LLC

NDC 70069-0013-25 · 25 VIAL in 1 CARTON / 5 mL in 1 VIAL · ANDA · View full market →

The short version

24 companies supply this market — deep enough that no single failure threatens the supply. Historically, drugs in this position went on to a new shortage within 90 days about 0.5% of the time — roughly 4× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$274.00
Reported to Texas DSHS · 2026 annual filing · Somerset Therapeutics, LLC

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$16
96 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.5%chance of a new FDA shortage posting for glycopyrrolate (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 4× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $42.13 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA211705
TE code
AP
Approval date
Mar 20, 2019
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Glycopyrrolate (Injection)

LabelerStrengthFirst seenLast seen
Accord Healthcare, Inc.,GLYCOPYRROLATE .2 mg/mLJul 15, 2026Sep 3, 2026
Gland Pharma LimitedGLYCOPYRROLATE .2 mg/mLJul 15, 2026Sep 3, 2026
HF Acquisition Co LLC, DBA HealthFirstGLYCOPYRROLATE .2 mg/mLJul 15, 2026Sep 3, 2026
Hikma Pharmaceuticals USA Inc.GLYCOPYRROLATE .2 mg/mLJul 15, 2026Sep 3, 2026
Medical Purchasing Solutions, LLCGLYCOPYRROLATE .2 mg/mLJul 15, 2026Sep 3, 2026
Solco Healthcare US, LLCGLYCOPYRROLATE .4 mg/2mLJul 15, 2026Sep 3, 2026
Solco Healthcare US, LLCGLYCOPYRROLATE .2 mg/mLJul 15, 2026Sep 3, 2026
Somerset Therapeutics, LLCGLYCOPYRROLATE .2 mg/mLJul 15, 2026Sep 3, 2026
Xiromed LLCGLYCOPYRROLATE .2 mg/mLJul 15, 2026Sep 3, 2026
Xiromed, LLCGLYCOPYRROLATE .2 mg/mLJul 15, 2026Sep 3, 2026
Amneal Pharmaceuticals LLCGLYCOPYRROLATE 4 mg/20mLJul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCGLYCOPYRROLATE .2 mg/mLJul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCGLYCOPYRROLATE .4 mg/2mLJul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCGLYCOPYRROLATE 1 mg/5mLJul 15, 2026Sep 2, 2026
BE Pharmaceuticals Inc.GLYCOPYRROLATE 4 mg/20mLJul 15, 2026Sep 2, 2026
BE Pharmaceuticals Inc.GLYCOPYRROLATE 1 mg/5mLJul 15, 2026Sep 2, 2026
BE Pharmaceuticals Inc.GLYCOPYRROLATE .2 mg/mLJul 15, 2026Sep 2, 2026
BE Pharmaceuticals Inc.GLYCOPYRROLATE .4 mg/2mLJul 15, 2026Sep 2, 2026
Caplin Steriles LimitedGLYCOPYRROLATE .2 mg/mLJul 15, 2026Sep 2, 2026
Caplin Steriles LimitedGLYCOPYRROLATE 4 mg/20mLJul 15, 2026Sep 2, 2026
Caplin Steriles LimitedGLYCOPYRROLATE .4 mg/2mLJul 15, 2026Sep 2, 2026
Caplin Steriles LimitedGLYCOPYRROLATE 1 mg/5mLJul 15, 2026Sep 2, 2026
Cardinal Health 107, LLCGLYCOPYRROLATE .2 mg/mLJul 15, 2026Sep 2, 2026
Civica, Inc.GLYCOPYRROLATE .2 mg/mLJul 15, 2026Sep 2, 2026
Henry Schein, Inc.GLYCOPYRROLATE .2 mg/mLJul 15, 2026Sep 2, 2026
HF Acquisition Co LLC, DBA HealthFirstGLYCOPYRROLATE 1 mg/5mLJul 15, 2026Sep 2, 2026
Jvet Pharmaceuticals LLCGLYCOPYRROLATE .2 mg/mLJul 15, 2026Sep 2, 2026
ProPharma DistributionGLYCOPYRROLATE .2 mg/mLJul 15, 2026Sep 2, 2026
Sandoz IncGLYCOPYRROLATE 4 mg/20mLJul 15, 2026Sep 2, 2026
Sandoz IncGLYCOPYRROLATE .2 mg/mLJul 15, 2026Sep 2, 2026
Sandoz IncGLYCOPYRROLATE .4 mg/2mLJul 15, 2026Sep 2, 2026
Sandoz IncGLYCOPYRROLATE 1 mg/5mLJul 15, 2026Sep 2, 2026
Xiromed LlcGLYCOPYRROLATE .2 mg/mLJul 15, 2026Sep 2, 2026
Lifestar Pharma LLCGLYCOPYRROLATE .2 mg/mLJul 15, 2026Aug 31, 2026
Meitheal Pharmaceuticals Inc.GLYCOPYRROLATE .2 mg/mLJul 15, 2026Aug 31, 2026
Nivagen Pharmaceuticals, Inc.GLYCOPYRROLATE .2 mg/mLJul 15, 2026Aug 31, 2026
Fresenius Kabi USA, LLCGLYCOPYRROLATE .2 mg/mLJul 15, 2026Aug 29, 2026
Alembic Pharmaceuticals Inc.GLYCOPYRROLATE .2 mg/mLJul 15, 2026Aug 28, 2026
Medical Purchasing Solutions, LLCGLYCOPYRROLATE 4 mg/20mLJul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Glycopyrrolate — NDC 70069-0013-25," retrieved September 3, 2026, https://drugdashboards.com/drug/70069001325.

Free to cite with attribution — see how the data is put together.